The estimated Net Worth of Scott M Coiante is at least $1.82 Milion dollars as of 7 October 2019. Mr. Coiante owns over 2,500 units of Aprea Therapeutics stock worth over $8,050 and over the last 10 years he sold APRE stock worth over $0. In addition, he makes $1,809,420 as Chief Financial Officer, Senior Vice President a Secretary at Aprea Therapeutics.
Scott has made over 1 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of APRE stock worth $37,500 on 7 October 2019.
The largest trade he's ever made was buying 2,500 units of Aprea Therapeutics stock on 7 October 2019 worth over $37,500. On average, Scott trades about 139 units every 0 days since 2014. As of 7 October 2019 he still owns at least 2,500 units of Aprea Therapeutics stock.
You can see the complete history of Mr. Coiante stock trades at the bottom of the page.
Scott M. Coiante serves as Chief Financial Officer, Senior Vice President, Secretary of the Company. Mr. Coiante joined Aprea from Agile Therapeutics (“Agile”), a women’s healthcare company, where he was Senior Vice President and Chief Financial Officer from 2010 to August 2019. While at Agile, he played a leadership role in the company and in the development of the internal finance and accounting infrastructure. Prior to joining Agile, from 2002 to 2010, he was Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.
As the Chief Financial Officer, Senior Vice President a Secretary of Aprea Therapeutics, the total compensation of Scott Coiante at Aprea Therapeutics is $1,809,420. There are 1 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
Scott Coiante is 53, he's been the Chief Financial Officer, Senior Vice President a Secretary of Aprea Therapeutics since 2019. There are 11 older and 5 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... a John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: